Growth fractions in breast cancers determined in situ with monoclonal antibody Ki-67.

Abstract

The monoclonal antibody Ki-67, prepared by our group,3 reacts with a nuclear antigen present in proliferating cells but absent in quiescent cells. A detailed cell cycle analysis showed that the Ki-67 antigen is expressed throughout the whole cell cycle, making the antibody suitable for the determination of the growth fraction of a benign or malignant human cell subset.4 We recently showed a highly significant correlation between the proportion of Ki-67 positive cells and the histological classification of malignant nonHodgkin's lymphomas into high and low grade malignancies.5 Thus the determination of the growth Accepted for publication 9 April 1986 fraction with Ki-67 might be a new and reliable prognostic marker for these tumours.The evaluation of cell kinetic data in mammary carcinomas should also be undertaken for tumour grading, as this can provide reproducible prognostic information.This paper reports on the immunohistological determination of the growth fraction with Ki-67 in a variety of breast tumours and compares the results with conventional histological grading. Material and methodsThirty benign mammary lesions and 160 mammary carcinomas from patients attending the gynaecology clinics at the Klinikum Steglitz, and the Medical School, Hannover, were studied. There were 148 invasive ductal carcinomas, nine invasive lobular carcinomas, three medullary carcinomas and no carcinomata in situ. Cryostat sections of biopsy specimens were immunostained with monoclonal antibody

Simultaneous flow cytometric analysis of surface markers and nuclear Ki‐67 antigen in leukemia and lymphoma

“…The results in patients with leukemia and lymphoma obtained in this study are in accordance with the Ki-67 labeling indices reported in previous investigations (3,5,8,11,13,18,21). However, one should be cautious in comparing the Ki-67 values of different tissue sites, as there might be marked heterogeneity.…”

“…A close relationship was demonstrated between Ki-67-positive cells and both 3H-thymidine uptake and the bromodeoxyuridine-labeling index (3 -5,7,16,18-2 1). These Thus far, immunostaining with Ki-67 has been performed primarily on frozen tissue sections (8,10,11,18,21) and cytospin preparations of cell suspensions (3-5,13). Flow cytometric detection of Ki-67-positive cells has been limited because of the nuclear localization of the antigen.…”

Predominance of the basal type and HER-2/neu type in brain metastasis from breast cancer

“…In all breast cancer types, the median proliferation index is considerably lower. 31 Intratumoural heterogeneity provides a hallmark of malignant neoplasm. Therefore, it is an open issue whether subclonal diversity can be reflected reliably by a single biopsy or section from steadily shrinking cancer specimens down to the size of core biopsies in the neoadjuvant setting.…”

An immunohistochemical assessment of cellular proliferation markers in head and neck squamous cell cancers

“…The Ki-67 monoclonal antibody recognises a nuclear antigen present in proliferating cells, but absent in resting cells (Gerdes et al, 1983). Since its original description by Gerdes et al (1983), Ki-67 antibody has been a valuable tool for estimating the proportion of proliferating cells in a number of tumour types (Gerdes et al, 1986;Shepherd et al, 1988). Gerdes' group has recently demonstrated a highly significant correlation between the proportion of Ki-67 positive cells and the histologic classification of lymphomas into high and low grade malignancies (Gerdes et al, 1984).…”